Cancer biotech ArriVent Biopharma files for a $100 million IPO - Renaissance Capital

Retrieved on: 2024-01-05 21:48:51

Tags for this article:

Lung cancer

Quinazolines

Oncogenes

Tyrosine kinase receptors

Tyrosine-kinase inhibitor

Antineoplastic drugs

Epidermal growth factor receptor

Non-small-cell lung cancer

Protein kinase inhibitor

Afatinib

T790M

Click the tags to see associated articles and topics

Cancer biotech ArriVent Biopharma files for a $100 million IPO - Renaissance Capital. View article details on HISWAI: https://www.renaissancecapital.com/IPO-Center/News/102633/Cancer-biotech-ArriVent-Biopharma-files-for-a-%24100-million-IPO

Excerpt

ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, filed on Friday with the SEC to raise up to $100 million in ...

Article found on: www.renaissancecapital.com

View Original Article